BofA lowered the firm’s price target on Travere Therapeutics (TVTX) to $43 from $47 and keeps a Buy rating on the shares after the FDA extended its review of the Filspari FSGS sNDA by three months and set a new target action date of April 13. The PDUFA extension is “a setback,” but the outlook for approval still looks positive, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Buy Rating Reaffirmed on Travere Therapeutics: Attractive Risk/Reward Despite FDA Delay and Near‑Term Catalyst Reset
- Top 5 Trending Stocks by Unusual Trading Volume, 1/14/26
- FDA Extends Review Timeline for Travere’s FILSPARI sNDA
- Leerink says Travere’s Filspari PDUFA extension removes worst case scenario
- Travere Therapeutics trading resumes